Coinbase CEO’s Biotech Firm Gets $130M to Fight Aging With AI, Genomics
NewLimit’s Series B raise adds fuel to Silicon Valley’s growing obsession with anti-aging science and biohacking immortality.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
Why this matters
This cryptocurrency story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on DecryptRelated market context
Strive Bitcoin Holdings Reach 35,595 BTC As Wall Street Raises Price Target 27%
TL;DR: TD Cowen reportedly raised its Strive share-price target from $44 to $56 after the Bitcoin treasury company expanded its ho...
Coinbase Partners With Thunes for Bank and Mobile-Wallet Payouts
Coinbase will supply stablecoin infrastructure while Thunes adds local payout connections; the partners have not specified launch...
Coinbase and Marqeta Bring 24/7 Stablecoin Card Spending to Millions of Merchants
Key Takeaways: Coinbase and Marqeta are taking a stab at stablecoin-based cards. Coinbase infrastructure makes it easy for busines...
Ethereum Institutional taps former Coinbase research chief David Duong as Head of US
Duong's leadership could accelerate Ethereum's integration into traditional finance, potentially reshaping institutional engagemen...
Coinbase partners with Thunes to expand stablecoin payments to 140 countries
This partnership could significantly enhance global financial inclusion by bridging digital and traditional payment systems, benef...
CME Targets October 19 Start For Bitcoin Cash And Uniswap Futures
CME Group has scheduled the introduction of Bitcoin Cash and Uniswap futures for October 19, giving institutional derivatives trad...